SIGA Strategy and Business Model

Executive Overview

SIGA is a niche biopharmaceutical company focused on health-security countermeasures, best known for TPOXX, its tecovirimat-based antiviral franchise for smallpox and related orthopox threats. Founded in 1995 and headquartered in New York, SIGA operates in a very different market from mainstream commercial pharma: most demand comes from governments and public-health agencies that stockpile countermeasures rather than from routine physician prescribing. That makes the company strategically narrow but economically distinctive.

Its business is built around maintaining, supplying, and extending the relevance of TPOXX, including oral and intravenous formulations, through regulatory work, government procurement, manufacturing oversight, and lifecycle management. The United States has historically been the core market, especially through the Strategic National Stockpile, while international growth depends on regulatory approvals and government preparedness budgets in selected countries. Revenue is therefore inherently lumpy, but repeat demand can still arise through stockpile replenishment, stability programs, and additional procurement rounds. In FY2024, SIGA reported revenue of #N/A. For readers trying to understand SIGA, the key issue is not portfolio breadth; it is whether the company can continue to deepen and defend the value of one strategically important countermeasure franchise.

SIGA at a Glance

Logo
Common name	SIGA
Full legal name	SIGA Technologies, Inc.
Headquarters	New York, New York, United States
Ownership	Public company; Nasdaq-listed, with no controlling shareholder publicly disclosed in recent annual filings
Ticker	SIGA
Exchange	NASDAQ
Market Cap	$308.77M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1995; pivoted toward biodefense in the early 2000s; oral TPOXX approved by the U.S. Food and Drug Administration in 2018; intravenous TPOXX approved in 2022
Industry or industries	Biopharmaceuticals; biodefense; medical countermeasures
Key products or services	TPOXX oral capsules, TPOXX intravenous formulation, government stockpile procurement, and related support activities
Geographic footprint	U.S.-centric revenue base with selected international regulatory and government-customer activity
Business segments as officially reported	One operating and reportable segment
Company website	https://www.siga.com

1. What Is the Strategy of SIGA?

SIGA’s public materials point to a focused, not diversified, strategy: protect and extend the TPOXX franchise as a core antiviral countermeasure for orthopox preparedness. The company is not trying to become a broad commercial pharma platform. Its strategy is closer to a specialized biodefense model built around government customers, regulatory durability, and dependable supply of a product that sits inside national preparedness plans.

1. 1a. What is the winning aspiration of SIGA?

   SIGA’s practical winning aspiration is to remain a trusted supplier of orthopox antiviral preparedness solutions, anchored by TPOXX. In public filings and investor communications, the company has emphasized protecting public health against smallpox and related orthopox threats while expanding the reach and usefulness of tecovirimat. Unlike a large diversified drug company, SIGA has not typically framed success around dozens of launches or a broad therapeutic portfolio. Winning, for SIGA, means keeping TPOXX embedded in stockpiling strategies, maintaining regulatory standing, and generating repeat procurement business over time.

   A reasonable synthesis of management’s public posture is that SIGA wants TPOXX to remain highly relevant to U.S. and allied-government preparedness planning, while adding international orders and additional evidence that can support franchise longevity.

2. 1b. Where does SIGA play?

   SIGA plays in a narrow part of the pharmaceutical market: biodefense and health-security countermeasures for orthopoxviruses such as smallpox and mpox. It does not compete in broad primary-care or specialty-drug markets. Its customers are mainly national governments, public-health agencies, and preparedness institutions rather than retail pharmacies or routine hospital formularies.

   Product-wise, SIGA plays in antiviral treatment rather than vaccines, though it competes indirectly with vaccine suppliers for preparedness budgets. Geography-wise, the company’s economic center is the United States, but it also targets selected international markets where regulatory approval and government stockpiling interest make procurement feasible.

3. 1c. How does SIGA plan to win?

   SIGA’s plan to win rests on four main ideas. First, it offers one of the few approved smallpox therapeutics, giving it relevance in a highly specialized market with substantial regulatory barriers. Second, it has built credibility with government buyers by operating in the stockpile ecosystem rather than trying to create ordinary commercial prescription demand. Third, it has broadened the franchise from oral to intravenous formulation, which improves usability in preparedness scenarios. Fourth, it runs a relatively lean operating model by outsourcing much of manufacturing while keeping control over the regulatory, technical, and government-facing parts of the value chain.

   In short, SIGA does not need mass-market scale to win. It needs to be reliable, approvable, contract-ready, and difficult to replace in preparedness planning.

4. 1d. What capabilities must SIGA have in place?

   The capabilities that matter most are unusually specific. SIGA needs strong regulatory science, including expertise related to the U.S. Food and Drug Administration’s Animal Rule framework and other nontraditional approval pathways relevant to smallpox countermeasures. It needs technical and quality-management capabilities to oversee Contract Manufacturing Organizations and maintain current Good Manufacturing Practice compliance. It also needs government-contracting discipline, because contract structure, delivery schedules, and acceptance criteria shape the economics of the business.

   Other essential capabilities include stability and shelf-life management, medical affairs support for orthopox use cases, pharmacovigilance, and disciplined cash and inventory planning. For a single-franchise company, operational reliability matters as much as scientific differentiation.

5. 1e. What management systems does SIGA require?

   SIGA needs management systems that fit a lumpy, contract-driven business. That includes rigorous quality systems, supplier oversight, batch-release controls, contract governance, and forecasting processes built around scenario planning rather than smooth quarterly demand. It also requires regulatory-compliance systems that can support multiple jurisdictions and post-approval obligations.

   Because the company is small and highly concentrated in one product family, management also needs strong capital-allocation discipline. Procurement timing can materially affect revenue and profit from one year to the next, so liquidity planning, board oversight, and conservative risk management are central to execution.

2. What Are the Current Strategic Initiatives of SIGA?

Based on recent public disclosures, SIGA’s current strategic initiatives are concentrated around extending and defending the TPOXX franchise rather than broadening into unrelated therapeutic areas.

• Maintain and refresh the U.S. stockpile position. The U.S. government has historically been SIGA’s most important customer. A central initiative is to fulfill deliveries, support replenishment cycles, and keep TPOXX aligned with Strategic National Stockpile requirements.
• Expand international government procurement. SIGA has worked to convert regulatory progress outside the U.S. into procurement opportunities with allied governments and public-health agencies. This matters because the company’s economics improve when it is not dependent on a single national buyer.
• Broaden the usability of tecovirimat. The intravenous formulation deepens the franchise by making the drug more practical for patients who cannot take oral therapy. More broadly, SIGA has continued to support evidence generation and regulatory work that can increase the relevance of tecovirimat in orthopox response planning.
• Support orthopox-related scientific and clinical evidence. During periods of mpox concern, tecovirimat has attracted attention well beyond smallpox preparedness. Publicly visible activity has included support for scientific, regulatory, and medical efforts that can clarify where and how the product fits in outbreak response, even when the U.S. label remains focused on smallpox.
• Preserve manufacturing readiness through external partners. Because SIGA does not run a large owned manufacturing network, it must keep Contract Manufacturing Organizations, supply planning, quality oversight, and inventory management in a ready state despite uneven order timing.
• Stay financially disciplined. Public disclosures suggest that SIGA continues to favor a focused, capital-light model rather than aggressive portfolio diversification. That means protecting liquidity, managing procurement-related volatility, and balancing reinvestment with shareholder returns.

An important strategic point is what SIGA is not doing. It does not appear to be pursuing a large acquisition-led roll-up or a broad internal discovery pipeline. Its strategic emphasis remains franchise extension, preparedness relevance, and execution.

3. What Is the Business Model of SIGA?

SIGA’s business model is best understood as a specialized government-biopharma model built around stockpiled preparedness products. It is not subscription-based, not consumer-facing, and not driven by ordinary prescription volume.

• What customers actually buy. Customers primarily buy finished courses of TPOXX, in oral or intravenous form, for preparedness stockpiles or related government needs. In some periods, SIGA also records smaller amounts of revenue tied to support, development, or contract-related activities.
• Recurring versus one-time revenue. Revenue is not recurring in the software sense, but it is partly repeat-driven. Governments replenish stockpiles, manage expiry schedules, and may place new orders as threat perceptions or budgets change. The timing is uneven, so the business can look volatile even when the underlying preparedness need persists.
• How pricing power works. SIGA has some pricing leverage because orthopox therapeutics are a narrow category with high regulatory barriers and few approved alternatives. But pricing is constrained by government procurement processes, contract negotiations, budget oversight, and the political sensitivity of preparedness spending.
• Why the business mix matters. Product sales typically matter most for revenue and profit. Smaller support or development-related revenue streams can be helpful, but they do not change the core economic reality that SIGA is overwhelmingly a TPOXX business.
• What drives gross margin and operating margin. Gross margin depends on contract pricing, manufacturing costs at external partners, batch economics, and the mix between product and non-product revenue. Operating margin can be strong in delivery-heavy years because SIGA’s internal cost base is relatively lean; the reverse is also true in quieter procurement periods.
• What drives cash generation. Cash generation benefits from low capital expenditure needs because manufacturing is largely outsourced. However, working capital can move around meaningfully based on inventory builds, delivery timing, and receivables from government customers.
• Revenue model. The revenue model is primarily contract-based product sales to government customers, supplemented by occasional contract-related service or development revenue. It is closer to a tender-and-delivery model than to a traditional pharmaceutical retail model.

The result is a company that can be attractive financially when procurement is active, but whose annual results should be interpreted through the lens of stockpile cycles rather than ordinary unit growth.

4. What Products and/or Services Does SIGA Sell?

SIGA’s product portfolio is highly concentrated. The company’s commercial identity is essentially the TPOXX franchise.

TPOXX oral capsules

Oral TPOXX is the flagship product and the main economic engine of the company. It is strategically important because it is the format most closely associated with stockpile procurement and broad preparedness planning. For most readers trying to understand SIGA’s revenue model, oral TPOXX is the first product to understand.

TPOXX intravenous formulation

The intravenous version of TPOXX expands the franchise for situations in which oral dosing is not appropriate or feasible. It may not yet match the oral formulation in commercial importance, but it strengthens SIGA’s value proposition to preparedness buyers by making the platform more usable across a wider range of clinical scenarios.

Related contract and support activities

SIGA may also generate smaller amounts of revenue tied to development support, contract services, or other activities associated with government relationships and product maintenance. These are economically secondary to product sales but can matter in explaining year-to-year revenue mix.

Legacy versus growth offerings

SIGA does not really have a legacy-versus-next-generation portfolio in the way diversified pharma companies do. Instead, the growth story is the extension of the same core molecule across formulations, jurisdictions, and evidence packages. That makes SIGA less of a product-launch story and more of a franchise-management story.

5. What Are the Key Competitors or Peers of SIGA?

SIGA operates in a narrow market, so a conventional competitor list can be misleading. The more useful view is a mix of direct drug competitors, vaccine substitutes, and biodefense procurement peers.

• Chimerix. Chimerix is the clearest direct pharmaceutical comparator because its smallpox antiviral TEMBEXA competes in the same broad treatment category, even though the products differ in mechanism, history, and commercial positioning.
• Bavarian Nordic. Bavarian Nordic’s JYNNEOS vaccine is preventive rather than therapeutic, but it competes for smallpox and mpox preparedness budgets and for mindshare in orthopox response planning.
• Emergent BioSolutions. Emergent is a close peer in government medical countermeasures, including smallpox-related products such as ACAM2000. It is not a direct antiviral substitute, but it competes in the same biodefense procurement ecosystem.
• Tonix Pharmaceuticals. Tonix has pursued orthopox-related vaccine development, making it a development-stage peer in the broader smallpox and mpox preparedness landscape.
• Soligenix. Soligenix is not a direct TPOXX competitor, but it is a useful niche peer because it also operates in specialized biodefense and government-backed countermeasure programs.
• NanoViricides. NanoViricides is an early-stage antiviral developer with orthopox ambitions. It is not a close commercial peer today, but it belongs in the emerging competitive landscape.

The most important takeaway is that SIGA has few true like-for-like competitors. In practice, it competes as much for procurement relevance and budget allocation as it does for ordinary therapeutic share.

6. What Is the Marketing Strategy of SIGA?

SIGA’s marketing strategy is fundamentally business-to-government and science-driven. This is not a classic branded-pharma marketing model with large physician detailing teams or direct-to-consumer advertising. Instead, the company’s marketing effort is built around regulatory credibility, government relationships, medical communication, and preparedness relevance.

In practical terms, that means SIGA’s marketing activity likely centers on public-health stakeholders, procurement officials, national-security agencies, and medical experts involved in orthopox response planning. Scientific publications, conference participation, policy engagement, and evidence communication matter more than mass-reach advertising. For international markets, tender support and local regulatory positioning are more important than conventional promotional spend.

Marketing is therefore a supporting capability rather than the primary source of differentiation. SIGA wins less by persuasive branding and more by being credible, approved, available, and technically supportable in a high-consequence preparedness market.

7. What Are the Key Customer Segments of SIGA?

SIGA’s customer base is concentrated and unusual relative to most biopharma companies.

• U.S. federal preparedness buyers. This is the most important segment, including agencies and programs associated with national stockpiling and biodefense preparedness.
• U.S. defense and national-security organizations. Military and related preparedness channels can matter because orthopox countermeasures have defense relevance as well as civilian public-health relevance.
• International governments and public-health authorities. Outside the U.S., SIGA’s addressable market consists mainly of sovereign buyers and health ministries that may choose to stockpile orthopox countermeasures.
• Clinical and outbreak-response institutions. In some settings, research networks, treatment programs, or outbreak-response mechanisms can influence use of tecovirimat, especially when orthopox outbreaks create renewed medical attention.

The company is not broadly diversified across thousands of customers. Customer concentration is one of the defining characteristics of the business. That creates risk, but it also means a small number of account relationships can drive large economic outcomes.

8. What Is the Sales Model of SIGA?

SIGA’s sales model is primarily direct and contract-based. In the United States, products are sold through government procurement processes rather than through broad commercial distribution. That means success depends on tendering, contract negotiation, regulatory status, delivery performance, and long-cycle account management.

Internationally, SIGA may work through a mix of direct government engagement and selected regional partners or distributors, depending on the jurisdiction. The key point is that sales are concentrated, high-value, and slow-moving compared with typical pharmaceutical prescription channels.

This channel structure has several implications. It increases customer intimacy with a small number of important buyers. It can support rational pricing because products are specialized and technically differentiated. But it also makes growth less linear: winning or losing a single procurement decision can materially affect results. For consultants, that kind of model creates demand for work on account strategy, tender readiness, pricing frameworks, and international market entry sequencing.

9. In What Geographies Does SIGA Operate?

SIGA’s commercial footprint is broader than its physical footprint. Operationally, the company is headquartered in New York and has historically maintained scientific and technical activity in Oregon, while relying heavily on external partners for manufacturing and other execution. It does not need a global owned factory network to serve its market.

From a customer perspective, the United States is the center of gravity. That is where the most important historical procurement relationships have existed. Outside the U.S., SIGA’s opportunity set is concentrated in selected countries and regions where governments maintain biodefense stockpiles and where tecovirimat has a viable regulatory path. Public milestones have included expansion into Europe, where Tecovirimat SIGA received regulatory approval in 2022.

So SIGA is geographically diversified in potential opportunity, but still concentrated in realized revenue. It serves a global preparedness problem through a relatively lean operating footprint.

10. Who Are the Owners of SIGA?

SIGA is a publicly traded company on Nasdaq under the ticker SIGA. As of recent annual and proxy disclosures, the company does not appear to have a publicly disclosed controlling shareholder. Ownership is split among institutional investors, insiders, and retail shareholders.

As with many small-cap public companies, the shareholder register changes over time. Public filings have typically shown large passive asset managers such as BlackRock and Vanguard among the larger institutional holders, but those positions are time-sensitive and should be checked against the latest filings for exact ownership levels.

11. How Is SIGA Organized?

As of its latest annual reporting, SIGA is organizationally simple. It reports as one operating and reportable segment rather than as a diversified collection of divisions. That fits the economics of the business: one dominant franchise, one primary customer group, and a lean internal structure.

At a practical level, the company can be understood as a set of functions organized around TPOXX. Those functions include regulatory and medical affairs, research and development, technical operations and manufacturing oversight, government sales and business development, legal and contracting, and corporate administration. Because SIGA outsources significant parts of execution, coordination across these functions matters more than large internal headcount.

It is not a holding company, not a franchise system, and not a portfolio of loosely connected assets. It is a focused operating company built around a small number of highly consequential processes.

12. How Does SIGA Operate?

Day to day, SIGA operates more like a specialized countermeasure orchestrator than a vertically integrated drug manufacturer. Its value creation depends on keeping the TPOXX franchise scientifically sound, regulatorily current, contract-ready, and physically deliverable.

The operating model includes forecasting demand with government customers, planning production with external manufacturers, sourcing pharmaceutical inputs, overseeing quality and release testing, managing stability and shelf-life programs, and coordinating deliveries into stockpile channels. On the commercial side, the company manages contract milestones, procurement discussions, and regulatory support for current and potential markets.

Operational complexity comes from several sources. Demand is lumpy and can be shaped by external events. Manufacturing must meet pharmaceutical quality standards even when order cadence is uneven. Supplier transitions are difficult because a regulated drug cannot easily be moved from one vendor to another without technical and regulatory work. And because SIGA is concentrated in one core product family, any disruption in manufacturing, quality, or procurement timing has an outsized effect on corporate results.

For that reason, operational reliability is not a back-office issue at SIGA; it is a central element of strategy.

13. What Are the Growth Opportunities for SIGA?

SIGA’s growth opportunities are real, but they are specific and constrained. The company’s path to growth is more about deepening a niche than opening many unrelated revenue streams.

• U.S. stockpile replenishment and lifecycle management. The most obvious opportunity is continued procurement, replenishment, and refresh activity tied to U.S. preparedness requirements.
• International government stockpiles. Additional countries may decide to stockpile orthopox therapeutics, especially where regulatory approvals already exist or can be obtained with manageable effort.
• Broader orthopox relevance. If the clinical and regulatory evidence base around tecovirimat strengthens, SIGA could deepen its role in planning for mpox and other orthopox events, even if country-specific labels and treatment pathways differ.
• More complete franchise penetration through intravenous TPOXX. The intravenous product can improve account value by making the TPOXX platform more versatile for emergency response and harder to displace.
• Adjacency opportunities in biodefense. Over time, SIGA could use its government relationships and preparedness credibility to evaluate adjacent countermeasure opportunities, though public materials suggest this has not yet been the main strategic emphasis.

The main constraints are equally clear: a single-product concentration, high customer concentration, dependence on government budgets, long regulatory cycles, and reliance on specialized external suppliers. For SIGA, growth is plausible, but it will likely remain episodic rather than smooth.

14. What Is the History of SIGA?

1. 1995 founding. SIGA was founded in 1995, with Kenneth Dillon associated with the company’s early formation and leadership.
2. Early evolution into biodefense. In the years after its founding, SIGA moved toward infectious-disease countermeasures and ultimately focused on orthopox preparedness, a strategic direction that became more relevant as biodefense spending increased in the early 2000s.
3. Development of ST-246/tecovirimat. The company’s defining scientific and commercial asset became ST-246, later commercialized as TPOXX.
4. Government-backed growth. As TPOXX advanced, SIGA built its business through government development support and procurement relationships rather than through conventional pharmaceutical commercialization.
5. PharmAthene litigation era. A long-running dispute with PharmAthene over rights related to ST-246 became one of the most important corporate events in SIGA’s middle history and shaped how the company was viewed by investors for years.
6. 2018 FDA approval. Oral TPOXX was approved by the U.S. Food and Drug Administration in 2018 for smallpox, a major milestone that transformed SIGA from a development-stage story into a commercial biodefense supplier.
7. 2022 franchise expansion. In 2022, SIGA added FDA approval for intravenous TPOXX, and the company also benefited from wider public attention to tecovirimat during the global mpox outbreak.
8. Recent strategic posture. In recent years, SIGA has remained focused on extending and monetizing the TPOXX franchise rather than using acquisitions to become a broad multi-asset pharmaceutical company.

15. What Are the Key Suppliers to SIGA?

Suppliers are strategically important to SIGA because the company relies heavily on third parties to make, test, package, and support its products. Public disclosures emphasize dependence on specialized external manufacturing and supply partners rather than on a broad, easily interchangeable supplier base.

• Active pharmaceutical ingredient suppliers. These vendors provide the drug substance inputs required for tecovirimat production.
• Drug-product Contract Manufacturing Organizations. These partners handle formulation, encapsulation, fill-finish, and related production steps for oral and intravenous products.
• Packaging and labeling vendors. Government stockpile products require exacting packaging, traceability, and release requirements.
• Testing and stability laboratories. Analytical testing, quality release, and shelf-life support are critical for stockpiled pharmaceuticals.
• Logistics and warehousing partners. These firms matter for delivery into stockpile channels, although the biggest strategic risk usually sits upstream in pharmaceutical manufacturing.

Specific supplier names are not broadly disclosed in the company’s mainstream public materials, and that is not unusual for a company of this size. The strategic point is that supplier concentration matters: changing vendors in a regulated pharmaceutical supply chain can require technology transfer, validation work, and in some cases regulatory submissions.

16. How Does the Supply Chain of SIGA Function?

SIGA’s supply chain is a regulated, outsourced pharmaceutical chain designed for preparedness products rather than everyday retail flow. Reliability and compliance matter more than maximum throughput.

1. Sourcing. SIGA secures drug-substance inputs and manufacturing capacity through specialized partners.
2. Manufacturing. External producers convert the active ingredient into finished oral or intravenous product under current Good Manufacturing Practice standards.
3. Testing and release. Batches undergo analytical testing, quality review, and release procedures before they can be delivered.
4. Packaging and stockpile readiness. Product must be packaged and documented to meet government acceptance and stockpile requirements.
5. Warehousing and delivery. Finished product is moved into inventory channels tied to government customers and national preparedness systems.
6. Lifecycle management. Stability monitoring, expiry planning, and replenishment cycles are part of the economics because these are stockpiled products with long but finite shelf lives.

What makes this supply chain strategically important is the combination of low volume relative to mass-market pharmaceuticals, very high consequence of failure, and uneven order cadence. SIGA must preserve readiness without the benefit of smooth commercial demand.

17. What Is the R&D Strategy of SIGA?

SIGA’s research and development strategy is focused and lifecycle-oriented. It is not a broad discovery engine with many molecules across many indications. Instead, R&D is centered on protecting and extending the tecovirimat franchise.

• Regulatory-supportive studies. Because smallpox approval pathways are unusual, SIGA’s R&D work has to support regulatory science, nonclinical evidence, pharmacokinetic bridging, and post-approval obligations.
• Formulation expansion. Development of the intravenous formulation shows that R&D at SIGA is partly about making the franchise more clinically usable and procurement-relevant.
• Orthopox evidence generation. Public interest in tecovirimat during mpox outbreaks has increased the importance of generating and interpreting data on orthopox use cases, even when the approved label differs by jurisdiction.
• Manufacturing and stability support. For a stockpiled antiviral, process knowledge, product stability, and shelf-life support are economically important forms of R&D.

An important nuance is that SIGA’s R&D burden is shaped by the biology and ethics of the category. Human efficacy studies in smallpox are not feasible, so regulatory progress depends heavily on animal models, pharmacology, and carefully structured evidence packages. That makes SIGA’s R&D function narrower than that of large pharma, but unusually dependent on regulatory sophistication.

18. What Is the Finance Strategy of SIGA?

SIGA’s finance strategy reflects a capital-light but volatile business model. The company does not need heavy capital expenditure to own factories at scale, because production is largely outsourced. That helps cash conversion when procurement deliveries are strong. At the same time, the business must be financed conservatively because revenue timing is uneven and inventory planning has to anticipate government demand.

Public disclosures over time suggest several recurring finance priorities:

• Preserve liquidity. Cash has to cover working-capital swings, supplier commitments, and the operational readiness required for government procurement.
• Manage volatility. Because a single order can materially affect annual results, SIGA’s finance function must plan around lumpiness rather than assume steady growth.
• Keep the model capital-light. Outsourcing helps avoid a high fixed-asset base, which is sensible for a company with concentrated demand.
• Return excess capital selectively. Historically, SIGA has shown willingness to return cash to shareholders through dividends, including special dividends in some periods, when liquidity permitted.
• Avoid unfocused expansion. Public behavior has generally favored franchise discipline over large acquisition-driven diversification.

Finance at SIGA is therefore less about maximizing leverage and more about matching a conservative balance-sheet posture to a specialized, episodic procurement model.

19. How Companies Like SIGA Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like SIGA use Umbrex when they need top-tier strategic and functional expertise without hiring a full consulting team with all the overhead. For a focused company like SIGA, that model is especially relevant: the company may need very high-end help on a narrow issue for a limited period, such as procurement strategy, international expansion, manufacturing resilience, or AI-enabled analytics, rather than a large multiyear transformation.

• Orthopox franchise strategy review, including how to prioritize U.S. stockpile defense, international expansion, and formulation-specific growth opportunities.
• International market-entry and tender strategy for selected government markets in Europe, the Middle East, or Asia-Pacific where orthopox preparedness spending is credible.
• Key-account strategy for government customers, including stakeholder mapping across health, defense, procurement, and public-health agencies.
• Supply-chain resilience assessment covering Contract Manufacturing Organizations, dual-sourcing options, tech-transfer risk, and delivery-readiness planning.
• Inventory and shelf-life analytics to improve replenishment planning, expiry management, and stockpile economics.
• Pricing and contracting strategy for government procurement, including scenario modeling around volume, option structures, and long-term readiness commitments.
• Operating-model design for a lean single-franchise biopharma company, including which capabilities should stay in-house and which should remain outsourced.
• Evidence-generation and lifecycle-management roadmap for tecovirimat, including prioritization of studies, regulatory sequencing, and partnership opportunities.
• Outbreak-response scenario planning, including demand surges, manufacturing bottlenecks, communications protocols, and cross-functional decision rights.
• Capital-allocation and adjacent-growth assessment, including whether SIGA should remain tightly focused on TPOXX or selectively add adjacent biodefense capabilities through partnerships or small deals.